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Predicting Long-Term
Survival in Pulmonary
Arterial Hypertension
More Than Just
Pulmonary Vascular Resistance*
Reda E. Girgis, MB, BCH
Baltimore, Maryland
“In the long run, men hit only what they aim at.
Therefore, though they should fail immediately,
they had better aim at something high”
—Henry David Thoreau (1)
Despite considerable advances in medical therapy for pul-
monary arterial hypertension (PAH), long-term mortality
remains high (2), largely as a result of right heart failure. It
is well established that measures of right ventricular (RV)
performance, rather than pulmonary artery pressure, are the
key determinants of survival (3,4). Hence, a major focus
of current research efforts is characterizing and under-
standing RV dysfunction. An important contribution is the
paper in this issue of the Journal by van de Veerdonk et al. (4).
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This group of investigators, who have an established track
record in cardiac magnetic resonance imaging (MRI) for
assessing RV structure and function, compared the prog-
nostic value of right ventricular ejection fraction (RVEF)
measured by MRI, with pulmonary vascular resistance
(PVR) by right heart catheterization, both at baseline and
after 1 year of PAH-specific therapies. PVR is a long-
accepted, albeit imperfect, measure of RV afterload (5) that
has been predictive of mortality in previous series. RVEF,
although clearly afterload dependent, also reflects intrinsic
RV contractility. As of yet, there have been limited data on
its prognostic utility.
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NIH/NHLBI R01 HL092831 and P50 HL084946.In a cohort of 110 patients with PAH, a lower baseline
RVEF was a strong predictor of death (p  0.001),
utperforming PVR (p  0.031). Although RVEF gener-
ally correlates inversely with PVR (6), the former was an
independent determinant of survival. Remarkably, an
RVEF above the optimal cut-off value of 35% was associ-
ated with similarly good long-term survival among patients
with a PVR below or above the cut-off value of 650
dynes·s·cm5 that best predicted mortality. Baseline cardiac
output (CO) and 6-min walk distance were also linked with
survival.
Follow-up right heart catheterization and MRI were
obtained after 1 year of therapy in 76 patients. In this group,
there was a small but significant decline in PVR that was
brought about primarily as a result of an increase in CO,
with minimal reduction in mean pulmonary artery pressure,
hemodynamic changes typically observed in response to
PAH therapy (7,8). RVEF was unchanged. However,
subsequent survival was significantly associated with
changes in RVEF, whereas no relationship was observed
between survival and change in PVR or CO. There was only
a weak correlation between changes in PVR and RVEF
(R  0.33). In 52 patients, PVR decreased by at least 15
dynes·s·cm5 (mean reduction of 284). Thirteen of these
patients had a fall in RVEF of 3% or more. Long-term
survival in this subset was dramatically worse than that in
the 39 patients with a fall in PVR combined with a stable or
increased RVEF, in whom survival exceeded 90% beyond 5
years.
This study raises several provocative issues. There is
general agreement that the RV response is the key deter-
minant of clinical outcomes in PAH. A key question is how
best to assess RV function. How can we identify a healthy
RV as opposed to one that is destined to fail? New York
Heart Association class and 6-min walk distance are likely
surrogate markers of CO, a major component of PVR. All
of these have previously been shown to predict survival, both
at baseline and in response to therapy, particularly during a
medium-range follow-up time of 2 to 3 years (7–9). A major
strength of this series by van de Veerdonk et al. (4) is the
relatively long median follow-up time of nearly 5 years.
Pulmonary hypertension clinicians, and certainly patients
and their families, are no longer satisfied with 1-, 3-, or even
5-year survival. We need to identify reliable surrogate
markers of durable, long-term survival. Medical therapy
would then be intensified until such an endpoint is met. If
not, and one could be fairly certain that the RV was about
to fail, then early referral for lung transplantation would be
considered.
A higher CO or stroke volume (SV) does not necessarily
indicate better function. A rise in SV can be achieved
through an increase in right ventricular end-diastolic vol-
ume (RVEDV) and/or improvement in RVEF. An inter-
esting observation from this study is that although CO was
significantly higher, and PVR lower, after 1 year of therapy,
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tantly, increasing RVEDV and RV end-systolic volume
after 1 year were the follow-up variables most significantly
associated with mortality, more so than change in RVEF.
According to the Laplace relationship, a dilated ventricular
chamber will develop higher wall tension, particularly when
combined with elevated intraluminal pressure. Thus, an
enlarged RV, even if capable of generating a normal CO
and maintaining normal filling pressures, may ultimately
decompensate because of persistently elevated wall stress
that increases myocardial oxygen demand and at the same
time impairs perfusion.
Such a scenario would presumably be reflected by an
elevated brain natriuretic peptide level, which unfortunately
was not reported. The relative importance of RV size versus
contractility is unclear. In a previous study from this group,
RVEDV and smaller left ventricular end-diastolic volume
and SV were significant predictors of mortality (10). If
RVEF is a good surrogate marker, what should the target
be? A baseline value of 35% was found to be the best cut-off
(4). Is there a similar threshold level at follow-up? Hope-
fully, these and other questions will be answered in the near
future as more MRI data are accumulated.
Currently, what is the role of cardiac MRI in PAH? This
study adds to the growing body of literature supporting the
utility of this noninvasive procedure in the management of
PAH (11,12). However, further validation and standardiza-
tion are required before its routine clinical application can
be recommended. In the meantime, clinical trials should
incorporate MRI variables as outcome measures. Another
important question is whether echocardiography could have
similar utility in RV assessment (12). Systolic RV function
can be reasonably quantified with the echo-derived tricuspid
annular plane systolic excursion, which has been associated
with survival in PAH (3). With use of a centralized
laboratory, a significant reduction in the ratio between RV
and LV end-diastolic areas was demonstrated in bosentan-
treated patients relative to placebo (13). However, the
reproducibility and reliability of echocardiography may
not be adequate for clinical decision making in routine
practice (11,12).
Our utopian goal in PAH therapy is to reduce PVR to
normal or near-normal levels. Although our research efforts
should continue to aim for this, unfortunately it may be an
unrealistic expectation in the majority of patients, despite
maximal medical therapy. Current guidelines for treatment
goals in PAH emphasize the attainment of New York Heart
Association functional class I to II symptoms, near-normal
exercise capacity, low brain natriuretic peptide level, the
absence of clinical right heart failure, and normal CO andright atrial pressure (14). Good RV systolic function as
measured by tricuspid annular plane systolic excursion is
also included, but serial assessments remain to be validated.
The current study by van de Veerdonk et al. (4), taken
together with their previous work (10), suggests that target-
ing a small RV with good contractile function may ulti-
mately prove to be the best surrogate marker of truly
long-term survival.
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